Using AI to diagnose melanoma in young patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop artificial intelligence algorithms to help distinguish melanoma from benign skin lesions in children, adolescents, and young adults. It focuses on creating algorithms based on dermatoscopic and histological images to enhance skin cancer screening and assist pathologists. The study will utilize data collected during routine clinical practice, requiring no additional time commitment from participants. Explainability methods will also be implemented to improve user understanding and trust in the AI systems.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\-

Exclusion Criteria:

* Patients without a melanoma or nevus diagnosis
* images with insufficient image quality

Where it's running

• Hospital Clínic de Barcelona
  Barcelona, Spain Recruiting
• University of Tübingen
  Tübingen, Germany Completed
• University of Florence
  Florence, Italy Completed

Study contacts

• Principal investigator: Titus J Brinker, PD Dr. med — German Cancer Research Center
• Study coordinator: Titus J Brinker, PD Dr. med
• Email: titus.brinker@nct-heidelberg.de
• Phone: +49 15175084347

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• AI-assisted whole-course management for safe medicine use in advanced solid tumors

  A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT07917351

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• AI-assisted and traditional workflows for admission diagnosis and management planning

  This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07760051

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.